安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Alectinib - Wikipedia
Alectinib was granted an accelerated approval by the US Food and Drug Administration (FDA) in December 2015, to treat people with advanced ALK-positive NSCLC whose disease worsened after, or who could not tolerate, treatment with crizotinib (Xalkori)
- Treatment Option for ALK+ NSCLC
Visit the official patient website for ALECENSA® (alectinib) See full safety for more information
- Alectinib: Uses, Dosage, Side Effects, Warnings - Drugs. com
Alectinib (Alecensa) is a type of cancer medication used to treat non-small cell lung cancer (NSCLC) in people who have an error in their anaplastic lymphoma kinase (ALK) gene
- Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK -positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
- Alectinib (oral route) - Side effects dosage - Mayo Clinic
Alectinib is used to treat non-small cell lung cancer (NSCLC) that has spread or to help prevent NSCLC from coming back after the tumor has been removed by surgery in patients whose tumors have an abnormal anaplastic lymphoma kinase (ALK) gene
- label - Food and Drug Administration
ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test
- Alectinib - NCI - National Cancer Institute
This page contains brief information about alectinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials
- Alectinib: Uses, Interactions, Mechanism of Action | DrugBank
Alectinib is a kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase
|
|
|